PLRZ News & Events

Stock futures are slightly higher, with pressure on technology and semiconductor names offset by steadier performance in other sectors. Technology leadership, particularly AI and semiconductor stocks, is showing some fatigue after a powerful second quarter rally. Chip shares experienced a notable pullback to begin the second half of the year, suggesting traders are taking profits after a strong run.Meanwhile, falling oil prices and easing geopolitical concerns have offered support to risk sentiment. Lower energy prices can help ease inflation pressures, potentially giving the Fed more flexibility later this year.The U.S. economy added 57,000 jobs in June, well below forecasts of 110,000 and a downwardly revised 129,000 in May. It is the lowest job gain in four months, but was roughly in line with the average monthly change over the prior 12 months. The unemployment rate dropped to 4.2% in June, down from 4.3% in May, as many people left the workforce.In pre-market trading, S&P 500 futures rose 0.35%, Nasdaq futures rose 0.54% and Dow futures rose 0.45%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Polyrizonup 8% after announcing results from its biocompatibility evaluation program for its proprietary Nasarix Allergy Blocker nasal sprayAeroVironmentup 5% after being awarded a $500M firm-fixed-price contract for the procurement of commercial counter-unmanned aerial systems and counter small-unmanned aerial systems capabilitiesRobinhoodup 3% after Mizuho raised the firm's price target on shares to $130 and maintained an Outperform rating on the sharesPalantirup 2% after DA Davidson upgraded the stock to Buy with a price target of $175, up from $165APi Groupup 1% after closing the acquisition of WTech Fire Group and boosting its FY26 outlookUP AFTER EARNINGS -Lindsayup 5%DOWN AFTER EARNINGS -Franklin Coveydown 19%LOWER -Bending Spoonsdown 6%, pulling back after its initial public offering yesterdayAlphabetdown 1% after the European Court of Justice confirmed the penalty imposed for Google Search's abuse of a dominant position in the context of the Android operating system

Polyrizon announced results from its biocompatibility evaluation program for its proprietary Nasarix Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria. The evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility profile of Nasarix, a drug-free mucoadhesive nasal spray intended to help reduce exposure to airborne allergens associated with seasonal allergic rhinitis. The completed testing program evaluated key biological safety endpoints identified for the device, including: cytotoxicity; sensitization; irritation / intracutaneous reactivity materialmediated pyrogenicity and acute systemic toxicity. In addition, long-term systemic toxicity was assessed through a toxicological risk assessment conducted in accordance with ISO 10993-17, demonstrating substantial safety margins across the product's constituent materials under intended conditions of use. The biocompatibility evaluation was based on the final Nasarix product configuration and supported by toxicological assessments of the formulation components, manufacturing processes, packaging materials, and intended patient exposure. According to the biological evaluation plan, the product consists of well-characterized materials with established safety profiles and utilizes a manufacturing process designed to minimize biological risk.

Polyrizon announced it has received central IRB approval to begin its first human clinical trial for Nasarix, the company's nasal spray designed to block airborne allergens.

Polyrizon announced the publication of U.S. patent application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery". The patent application covers Polyrizon's proprietary Trap & Target mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.